Related Experiment Video

Updated: Jul 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Do beta-tubulin mutations have a role in resistance to chemotherapy?

Helen K Berrieman1, Michael J Lind, Lynn Cawkwell

  • 1Postgraduate Medical Institute, University of Hull, UK. H.K.Berrieman@medschool.hull.ac.uk

The Lancet. Oncology
|March 9, 2004
PubMed

Insights

Beta-tubulin mutations are rare in cancer patients and unlikely to cause drug resistance. Studies revealed that previous findings were due to non-functional beta-tubulin pseudogenes, not actual gene mutations.

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • Beta-tubulin is a key target for antitubulin cancer drugs.
  • Initial studies suggested beta-tubulin mutations confer drug resistance in clinical samples.
  • The presence of highly homologous beta-tubulin pseudogenes complicates mutation detection.

Purpose of the Study:

  • To clarify the role of beta-tubulin mutations in antitubulin drug resistance.
  • To review the beta-tubulin gene family and its pseudogenes.
  • To reconcile conflicting findings on beta-tubulin mutations in clinical settings.

Main Methods:

  • Literature review of studies investigating beta-tubulin mutations.
  • Analysis of the beta-tubulin gene family, including pseudogenes.
  • Comparison of mutation data with antitubulin drug resistance phenotypes.

Main Results:

  • Observed mutations in early studies were attributed to sequencing non-functional beta-tubulin pseudogenes.
  • At least nine beta-tubulin pseudogenes exist with high sequence homology to the functional gene.
  • Subsequent research indicates beta-tubulin mutations are rare in clinical samples.

Conclusions:

  • Beta-tubulin mutations are uncommon in patients treated with antitubulin agents.
  • Pseudogene interference is a significant factor in previous controversial findings.
  • Beta-tubulin mutations are unlikely to be a major mechanism of drug resistance in cancer.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...